Fortress Investment Group’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

Fortress Investment Group’s Portfolio CYAD Stock Details CYAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,500,000	Closed	-$6.23M	–	41
2023 Q1	$6.23M	Hold	6,500,000	–	–	1.08%	4
2022 Q4	$3.2M	Hold	6,500,000	–	–	0.31%	9
2022 Q3	$8.97M	Hold	6,500,000	–	–	0.91%	9
2022 Q2	$11.2M	Hold	6,500,000	–	–	1.13%	12
2022 Q1	$15.8M	Hold	6,500,000	–	–	0.86%	13
2021 Q4	$23.8M	Buy	+6,500,000	New	+$27.3M	0.91%	10

Other funds holding CYAD

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Fortress Investment Group's CYAD Position: Q2 2023 in Review

Fortress Investment Group sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q2 2023, closing a stake of 6,500,000 shares — an estimated $6.23M sold.

Fortress Investment Group first reported a position in CYAD in Q4 2021 and held it in 6 quarters. The position peaked at $23.8M in Q4 2021. 2 funds tracked by Wall St. Rank hold CYAD as of Q2 2023.

Fortress Investment Group reported no remaining Celyad Oncology SA American Depositary Shares position as of Q2 2023 after selling out during the quarter.
Fortress Investment Group sold 6,500,000 Celyad Oncology SA American Depositary Shares shares in Q2 2023, an estimated $6.23M.
Fortress Investment Group first reported a position in Celyad Oncology SA American Depositary Shares in Q4 2021 and held it in 6 quarters.
Fortress Investment Group's Celyad Oncology SA American Depositary Shares position peaked at $23.8M in Q4 2021.
2 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q2 2023.

Based on Fortress Investment Group's 13F filing for Q2 2023, filed 14 Aug 2023.